Ipilimumab reinduction study in Advanced Melanoma: CA184-243

• Research type

  Research Study

• Full title

  A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Advanced Melanoma who Progressed after Initially Achieving Disease Control with Ipilimumab Therapy

• IRAS ID

  117253

• Contact name

  Christian Ottensmeier

• Contact email

  c.h.ottensmeier@soton.ac.uk

• Sponsor organisation

  Bristol-Myers Squibb International Corporation

• Eudract number

  2012-003291-38

• Clinicaltrials.gov Identifier

  NCT01709162

• REC name

  Wales REC 3

• REC reference

  12/WA/0388

• Date of REC Opinion

  30 Apr 2013

• REC opinion

  Further Information Favourable Opinion